Co-occurring Medical Disorders

  • Aaron MeyerEmail author


Substance use can lead to significant medical consequences. Development of these associated diagnoses can be common or rare, and they can vary depending on substance used, frequency, duration, and individual vulnerability. This chapter is organized by substance class and affected organ systems that can vary by substance. These complications may be transient and resolve with substance cessation but can also be irreversible. Prognosis may not be dose-dependent. Some risks are associated with route of administration, independent of substance. Additionally, maternal-fetal risks are possible with complications ranging from low birth weight to fetal demise. By systematically reviewing physical effects of substance use, this structured framework will assist busy clinicians with patient care considerations.


Substance use  Medical complications  Side effects  Consequences  Physical 


  1. 1.
    Koguchi K, Nakatsuji Y, Abe K, Sakoda S. Wernicke's encephalopathy after glucose infusion. Neurology. 2004;62(3):512.CrossRefGoogle Scholar
  2. 2.
    Malamud N, Skillicorn SA. Relationship between the Wernicke and the Korsakoff syndrome; a clinicopathologic study of seventy cases. AMA Arch Neurol Psychiatry. 1956;76(6):585–96.CrossRefGoogle Scholar
  3. 3.
    Beilin LJ, Puddey IB. Alcohol and hypertension: an update. Hypertension. 2006;47(6):1035–8.CrossRefGoogle Scholar
  4. 4.
    Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513–23.CrossRefGoogle Scholar
  5. 5.
    Runyon BA. A primer on detecting cirrhosis and caring for these patients without causing harm. Int J Hepatol. 2011;2011:801983.CrossRefGoogle Scholar
  6. 6.
    Latvala J, Parkkila S, Niemelä O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res. 2004;28(4):619–24.CrossRefGoogle Scholar
  7. 7.
    Joya X, Friguls B, Ortigosa S, et al. Determination of maternal-fetal biomarkers of prenatal exposure to ethanol: a review. J Pharm Biomed Anal. 2012;69:209–22.CrossRefGoogle Scholar
  8. 8.
    Girard DE, Kumar KL, McAfee JH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am. 1987;1(2):321–34.CrossRefGoogle Scholar
  9. 9.
    Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952–60.CrossRefGoogle Scholar
  10. 10.
    Chan TT, Leung WC, Li V, et al. Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study. Psychogeriatrics. 2017;17(5):310–6.CrossRefGoogle Scholar
  11. 11.
    Wikner BN, Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol. 2011;31(3):356–9.CrossRefGoogle Scholar
  12. 12.
    Bhattacharya P, Taraman S, Shankar L, Chaturvedi S, Madhavan R. Clinical profiles, complications, and disability in cocaine-related ischemic stroke. J Stroke Cerebrovasc Dis. 2011;20(5):443–9.CrossRefGoogle Scholar
  13. 13.
    Devlin RJ, Henry JA. Clinical review: major consequences of illicit drug consumption. Crit Care. 2008;12(1):202.CrossRefGoogle Scholar
  14. 14.
    Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data. Ann Intern Med. 2018;170:31.CrossRefGoogle Scholar
  15. 15.
    Thörn SE, Wattwil M, Lindberg G, Säwe J. Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol Scand. 1996;40(2):177–86.CrossRefGoogle Scholar
  16. 16.
    Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44.CrossRefGoogle Scholar
  17. 17.
    Keefer L, Drossman DA, Guthrie E, et al. Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016.Google Scholar
  18. 18.
    Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14(11):747–53.CrossRefGoogle Scholar
  19. 19.
    Hackam DG. Cannabis and stroke: systematic appraisal of case reports. Stroke. 2015;46(3):852–6.CrossRefGoogle Scholar
  20. 20.
    Neunteufl T, Heher S, Kostner K, et al. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol. 2002;39(2):251–6.CrossRefGoogle Scholar
  21. 21.
    Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol. 1998;42(6):535–47.CrossRefGoogle Scholar
  22. 22.
    Ali MU, Fitzpatrick-Lewis D, Miller J, et al. Screening for abdominal aortic aneurysm in asymptomatic adults. J Vasc Surg. 2016;64(6):1855–68.CrossRefGoogle Scholar
  23. 23.
    Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRefGoogle Scholar
  24. 24.
    Hinsberger A, Sharma V, Mazmanian D. Cognitive deterioration from long-term abuse of dextromethorphan: a case report. J Psychiatry Neurosci. 1994;19(5):375–7.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Mvula MM, Miller JM, Ragan FA. Relationship of phencyclidine and pregnancy outcome. J Reprod Med. 1999;44(12):1021–4.PubMedGoogle Scholar
  26. 26.
    Tang N, Wu Y, Zhou B, Wang B, Yu R. Green tea, black tea consumption and risk of lung cancer: a meta-analysis. Lung Cancer. 2009;65(3):274–83.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of California, San DiegoSan DiegoUSA

Personalised recommendations